BR112012026239A2 - polinucleotídeo isolado, cassete de expressão, célula hospedeira, polipeptídeo isolado, animal transgênico não humano que foi alterado para expressar um polipeptídeo mutante com resistência a alk, anticorpo que se liga especificamente a um polipeptídeo mutante com resistência a alk, kit para detecção de uma mutação com resistência a inibidor de alk em uma amostra biológica, e, métodos para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pf-02341066 em um paciente, de reduzir especificamente a expressão de um mutante com resistência a alk, de tratamento de um câncer associado com atividade de alç aberrante que é reistente a pelo mneos um inibidor de cinase de molécula pequena de alk, de traatamento de um câncer aberrante que é resistente a pf-02341066, de identificação de um agente capaz de inibir a atividade cinase de um mutante com resistência a alk ou proteína de fusão de alk - Google Patents
polinucleotídeo isolado, cassete de expressão, célula hospedeira, polipeptídeo isolado, animal transgênico não humano que foi alterado para expressar um polipeptídeo mutante com resistência a alk, anticorpo que se liga especificamente a um polipeptídeo mutante com resistência a alk, kit para detecção de uma mutação com resistência a inibidor de alk em uma amostra biológica, e, métodos para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pf-02341066 em um paciente, de reduzir especificamente a expressão de um mutante com resistência a alk, de tratamento de um câncer associado com atividade de alç aberrante que é reistente a pelo mneos um inibidor de cinase de molécula pequena de alk, de traatamento de um câncer aberrante que é resistente a pf-02341066, de identificação de um agente capaz de inibir a atividade cinase de um mutante com resistência a alk ou proteína de fusão de alkInfo
- Publication number
- BR112012026239A2 BR112012026239A2 BR112012026239A BR112012026239A BR112012026239A2 BR 112012026239 A2 BR112012026239 A2 BR 112012026239A2 BR 112012026239 A BR112012026239 A BR 112012026239A BR 112012026239 A BR112012026239 A BR 112012026239A BR 112012026239 A2 BR112012026239 A2 BR 112012026239A2
- Authority
- BR
- Brazil
- Prior art keywords
- alk
- resistant
- inhibitor
- biological sample
- resistance
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
polinucleotídeo isolado, cassete de expressão, célula hospedeira, polipeptídeo isolado, animal transgênico não humano que foi alterado para expressar um polipeptídeo mutante com resistência a alk, anticorpo que se liga especificamente a um polipeptídeo mutante com resistência a alk, kit para detecção de uma mutação com resistência a inibidor de alk em uma amostra biológica, e, métodos para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para dianosticar um câncer que é resistente a ou é provavel que desenvolva resistência a pf-02341066 em um paciente, de reduzir especificamente a expressão de um mutante com resistência a alk, de tratamento de um câncer associado com atividade de alk aberrante que é resistente a pelo menos um inibidor de cinase de molécula pequena de alk, de tratamento de um câncer associado com atividade de alk aberrante que é resistente a pf-02341066, de identificação de um agente capaz de inibir a atividade cinase de um mutante com resistência a alk ou proteína de fusão de alk. são fornecidas neste documento composições e métodos para diagnóstico e tratamento de um câncer que é resistente a pelo menos um inibidor de cinase de cinase de linfoma anaplásico (alk). a presente invenção baseia-se na descoberta de mutações dentro da alk que conferem resistência a pelo menos uma mutação com resistência a inibidor de alk são fornecidos e encontram utilização em métodos e composições úteis no diagnóstico, prognóstico e/ou tratamento de doenças associadas com atividade de alk aberrante, mais particularmente, aquelas que são resistentes a pelo menos um inibidor de cinase de alk. métodos e composições são também fornecidos para identificação de agentes que podem inibir a atividade cinase e/ou reduzir o nível de expressão dos mutantes de resistência a alk.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/761,050 US8383793B2 (en) | 2010-04-15 | 2010-04-15 | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
PCT/US2011/032204 WO2011130340A1 (en) | 2010-04-15 | 2011-04-13 | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (alk) kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012026239A2 true BR112012026239A2 (pt) | 2018-06-26 |
Family
ID=44314994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012026239A BR112012026239A2 (pt) | 2010-04-15 | 2011-04-13 | polinucleotídeo isolado, cassete de expressão, célula hospedeira, polipeptídeo isolado, animal transgênico não humano que foi alterado para expressar um polipeptídeo mutante com resistência a alk, anticorpo que se liga especificamente a um polipeptídeo mutante com resistência a alk, kit para detecção de uma mutação com resistência a inibidor de alk em uma amostra biológica, e, métodos para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pf-02341066 em um paciente, de reduzir especificamente a expressão de um mutante com resistência a alk, de tratamento de um câncer associado com atividade de alç aberrante que é reistente a pelo mneos um inibidor de cinase de molécula pequena de alk, de traatamento de um câncer aberrante que é resistente a pf-02341066, de identificação de um agente capaz de inibir a atividade cinase de um mutante com resistência a alk ou proteína de fusão de alk |
Country Status (10)
Country | Link |
---|---|
US (2) | US8383793B2 (pt) |
EP (1) | EP2558490B1 (pt) |
JP (2) | JP6223822B2 (pt) |
KR (1) | KR20130064067A (pt) |
CN (1) | CN103201286B (pt) |
AU (1) | AU2011240636B2 (pt) |
BR (1) | BR112012026239A2 (pt) |
CA (1) | CA2796306A1 (pt) |
RU (1) | RU2012148450A (pt) |
WO (1) | WO2011130340A1 (pt) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009103061A2 (en) * | 2008-02-15 | 2009-08-20 | The Children's Hospital Of Philadelphia | Methods and compositions for identifying, diagnosing, and treating neuroblastoma |
US20110206691A1 (en) * | 2008-02-15 | 2011-08-25 | Mosse Yael P | Methods and Compositions for Treating Neuroblastoma |
JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
CN103965200B (zh) | 2008-09-22 | 2016-06-08 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物 |
SI2725028T1 (sl) | 2008-10-22 | 2016-10-28 | Array Biopharma, Inc. | Substituirane spojine pirazolo(1,5-)pirimidina kot vmesne spojine v sintezi inhibitorjev TRK kinaze |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
EP3534128A3 (en) | 2009-08-13 | 2020-01-08 | Teleflex Life Sciences Unlimited Company | Pressure indicator |
KR102132405B1 (ko) | 2010-05-20 | 2020-07-09 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
US20130288240A1 (en) * | 2010-05-21 | 2013-10-31 | Cell Signaling Technology, Inc. | Alk and ros kinase in cancer |
US10549054B2 (en) | 2011-02-02 | 2020-02-04 | Teleflex Life Sciences Unlimited Company | Artificial airway |
AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
MY169142A (en) | 2012-03-06 | 2019-02-18 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
JP6205216B2 (ja) * | 2012-09-24 | 2017-09-27 | アークレイ株式会社 | 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
CN104513253A (zh) | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
AU2015243241A1 (en) | 2014-04-10 | 2016-11-03 | Memorial Sloan-Kettering Cancer Center | A novel isoform of Anaplastic Lymphoma Kinase and its uses |
US9428812B2 (en) * | 2014-04-28 | 2016-08-30 | Insight Genetics, Inc. | Kit comprising primers for amplifying ALK kinase domain nucleic acids |
RS64122B1 (sr) | 2014-11-16 | 2023-05-31 | Array Biopharma Inc | Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogensulfata |
US20180000906A1 (en) * | 2015-01-16 | 2018-01-04 | Vedantra Pharmaceuticals, Inc. | Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof |
AU2016270321B2 (en) * | 2015-05-29 | 2020-09-10 | Ignyta, Inc. | Compositions and methods for treating patients with RTK mutant cells |
AU2016344058A1 (en) | 2015-10-26 | 2018-05-17 | Array Biopharma Inc. | Point mutations in Trk inhibitor-resistant cancer and methods relating to the same |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
RU2751767C2 (ru) | 2016-04-04 | 2021-07-16 | Локсо Онколоджи, Инк. | Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида |
CA3024603A1 (en) | 2016-05-18 | 2017-11-23 | Charles Todd Eary | Process for the preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
CN107885972B (zh) * | 2016-09-30 | 2021-07-27 | 广州华大基因医学检验所有限公司 | 一种基于单端测序的融合基因检测方法及其应用 |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
CN110716042A (zh) * | 2019-10-23 | 2020-01-21 | 郑州大学 | 一种用于卵巢癌早期筛查和诊断的血清蛋白标志物、试剂盒及检测方法 |
CN111235272B (zh) * | 2020-01-10 | 2023-07-07 | 厦门艾德生物医药科技股份有限公司 | 一次性检测肺癌多重基因突变的组合物及其应用 |
WO2021216920A1 (en) | 2020-04-22 | 2021-10-28 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
CN112391390A (zh) * | 2020-11-19 | 2021-02-23 | 山西大学 | 飞蝗网格蛋白重链基因及其靶向dsRNA的合成与应用 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
DE3785591T2 (de) | 1986-01-10 | 1993-09-02 | Amoco Corp | Kompetitiver homogener test. |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5107065A (en) | 1986-03-28 | 1992-04-21 | Calgene, Inc. | Anti-sense regulation of gene expression in plant cells |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5225326A (en) | 1988-08-31 | 1993-07-06 | Research Development Foundation | One step in situ hybridization assay |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
EP0950707B1 (en) | 1989-07-25 | 2009-02-18 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
BR9106653A (pt) | 1990-07-10 | 1993-06-08 | Smithkline Beecham Corp | Oxamidas |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
KR100236506B1 (ko) | 1990-11-29 | 2000-01-15 | 퍼킨-엘머시터스인스트루먼츠 | 폴리머라제 연쇄 반응 수행 장치 |
US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
CA2218875C (en) | 1991-07-23 | 2000-11-07 | The Research Foundation Of State University Of New York | Improvements in the in situ pcr |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5270184A (en) | 1991-11-19 | 1993-12-14 | Becton, Dickinson And Company | Nucleic acid target generation |
US5545524A (en) | 1991-12-04 | 1996-08-13 | The Regents Of The University Of Michigan | Compositions and methods for chromosome region-specific probes |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
ATE256738T1 (de) | 1992-10-30 | 2004-01-15 | Gen Hospital Corp | Ein neues zellzyklus kontrollprotein |
AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
US6696548B2 (en) * | 1993-12-03 | 2004-02-24 | St. Jude Children's Research Hospital | Antibodies for recognition of alk protein tyrosine/kinase receptor |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
JP3189000B2 (ja) | 1994-12-01 | 2001-07-16 | 東ソー株式会社 | 特定核酸配列の検出方法 |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US5710029A (en) | 1995-06-07 | 1998-01-20 | Gen-Probe Incorporated | Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product |
GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
US5612473A (en) | 1996-01-16 | 1997-03-18 | Gull Laboratories | Methods, kits and solutions for preparing sample material for nucleic acid amplification |
EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
US6121489A (en) | 1996-03-05 | 2000-09-19 | Trega Biosciences, Inc. | Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein |
JP3898228B2 (ja) | 1996-04-12 | 2007-03-28 | ザ パブリック ヘルス リサーチ インスティチュート オブ ザ シティー オブ ニューヨーク インク | 検出プローブ、キット及びアッセイ |
US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
WO1999023254A1 (en) | 1997-10-31 | 1999-05-14 | Affymetrix, Inc. | Expression profiles in adult and fetal organs |
US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
ATE440963T1 (de) | 1998-07-02 | 2009-09-15 | Gen Probe Inc | Molekulare fackeln |
US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6303305B1 (en) | 1999-03-30 | 2001-10-16 | Roche Diagnostics, Gmbh | Method for quantification of an analyte |
DE60014762T2 (de) | 1999-05-24 | 2005-10-13 | Tosoh Corp., Shinnanyo | Methode zum Nachweis von Ribonukleinsäuren |
US20030198627A1 (en) | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
CA2524572C (en) | 2003-05-01 | 2018-07-10 | Gen-Probe Incorporated | Oligonucleotides comprising a molecular switch having enhanced sensitivity to the presence of a mismatch |
US20080051419A1 (en) | 2006-07-26 | 2008-02-28 | Pfizer Inc. | Amine derivatives useful as anticancer agents |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
EP2042191B1 (en) * | 2007-09-28 | 2013-01-02 | Roberto Chiarle | Anaplastic Lymphoma Kinase (ALK) as oncoantigen for lymphoma vaccination |
WO2009103061A2 (en) * | 2008-02-15 | 2009-08-20 | The Children's Hospital Of Philadelphia | Methods and compositions for identifying, diagnosing, and treating neuroblastoma |
TWI518325B (zh) * | 2010-02-04 | 2016-01-21 | 自治醫科大學 | 對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療 |
-
2010
- 2010-04-15 US US12/761,050 patent/US8383793B2/en not_active Expired - Fee Related
-
2011
- 2011-04-13 BR BR112012026239A patent/BR112012026239A2/pt not_active IP Right Cessation
- 2011-04-13 CN CN201180023776.XA patent/CN103201286B/zh not_active Expired - Fee Related
- 2011-04-13 CA CA2796306A patent/CA2796306A1/en not_active Abandoned
- 2011-04-13 AU AU2011240636A patent/AU2011240636B2/en not_active Ceased
- 2011-04-13 KR KR1020127029988A patent/KR20130064067A/ko not_active Application Discontinuation
- 2011-04-13 EP EP11721840.4A patent/EP2558490B1/en not_active Not-in-force
- 2011-04-13 JP JP2013505074A patent/JP6223822B2/ja not_active Expired - Fee Related
- 2011-04-13 WO PCT/US2011/032204 patent/WO2011130340A1/en active Application Filing
- 2011-04-13 RU RU2012148450/10A patent/RU2012148450A/ru not_active Application Discontinuation
-
2013
- 2013-02-20 US US13/771,948 patent/US9458508B2/en active Active
-
2016
- 2016-10-03 JP JP2016195911A patent/JP2017018141A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6223822B2 (ja) | 2017-11-01 |
US20110256546A1 (en) | 2011-10-20 |
WO2011130340A1 (en) | 2011-10-20 |
KR20130064067A (ko) | 2013-06-17 |
JP2017018141A (ja) | 2017-01-26 |
RU2012148450A (ru) | 2014-05-20 |
AU2011240636A1 (en) | 2012-11-15 |
AU2011240636B2 (en) | 2014-10-02 |
CN103201286B (zh) | 2017-05-03 |
EP2558490B1 (en) | 2016-12-14 |
JP2013534804A (ja) | 2013-09-09 |
CN103201286A (zh) | 2013-07-10 |
US9458508B2 (en) | 2016-10-04 |
CA2796306A1 (en) | 2011-10-20 |
EP2558490A1 (en) | 2013-02-20 |
US20130244893A1 (en) | 2013-09-19 |
US8383793B2 (en) | 2013-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012026239A2 (pt) | polinucleotídeo isolado, cassete de expressão, célula hospedeira, polipeptídeo isolado, animal transgênico não humano que foi alterado para expressar um polipeptídeo mutante com resistência a alk, anticorpo que se liga especificamente a um polipeptídeo mutante com resistência a alk, kit para detecção de uma mutação com resistência a inibidor de alk em uma amostra biológica, e, métodos para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pf-02341066 em um paciente, de reduzir especificamente a expressão de um mutante com resistência a alk, de tratamento de um câncer associado com atividade de alç aberrante que é reistente a pelo mneos um inibidor de cinase de molécula pequena de alk, de traatamento de um câncer aberrante que é resistente a pf-02341066, de identificação de um agente capaz de inibir a atividade cinase de um mutante com resistência a alk ou proteína de fusão de alk | |
Buczkowicz et al. | Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations | |
Jones et al. | Cardiomyocytes from AKAP7 knockout mice respond normally to adrenergic stimulation | |
Ruiz-Hernandez et al. | Environmental chemicals and DNA methylation in adults: a systematic review of the epidemiologic evidence | |
Liu et al. | Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation | |
Brissot et al. | Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia | |
Shojaee et al. | Erk negative feedback control enables pre-B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia | |
Claus et al. | Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia | |
Wiklund et al. | Macrophage inhibitory cytokine‐1 (MIC‐1/GDF15): a new marker of all‐cause mortality | |
Vulto-van Silfhout et al. | Mutations affecting the SAND domain of DEAF1 cause intellectual disability with severe speech impairment and behavioral problems | |
Liu et al. | PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53 | |
BR112015023783A2 (pt) | método para diagnóstico e tratamento de metastase no câncer | |
Guilpain et al. | The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis | |
Steinert et al. | Mapping of the contraction-induced phosphoproteome identifies TRIM28 as a significant regulator of skeletal muscle size and function | |
Eadie et al. | ABCB1 overexpression is a key initiator of resistance to tyrosine kinase inhibitors in CML cell lines | |
KR20180018507A (ko) | 미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측 | |
Jacquemin et al. | Underexpression and abnormal localization of ATM products in ataxia telangiectasia patients bearing ATM missense mutations | |
Baiamonte et al. | Attenuation of Rhes activity significantly delays the appearance of behavioral symptoms in a mouse model of Huntington's disease | |
Francica et al. | Functional radiogenetic profiling implicates ERCC6L2 in non-homologous end joining | |
Trejo et al. | Mutationally activated PIK3CAH1047R cooperates with BRAFV600E to promote lung cancer progression | |
Davies et al. | The role of whole blood impedance aggregometry and its utilisation in the diagnosis and prognosis of patients with systemic inflammatory response syndrome and sepsis in acute critical illness | |
Ramaswamy et al. | Gsα controls cortical bone quality by regulating osteoclast differentiation via cAMP/PKA and β-catenin pathways | |
Ma et al. | JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms | |
Yin et al. | Toxicological assessment of trace β-diketone antibiotic mixtures on zebrafish (Danio rerio) by proteomic analysis | |
Suleiman et al. | Anti‐nucleosome antibodies as a disease activity marker in patients with systemic lupus erythematosus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2509 DE 05/02/2019. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |